Using MRI to improve cancer radiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot phase clinical trial aims to optimize magnetic resonance imaging (MRI) sequences using the Alberta linac-MR P3 system for adult cancer patients undergoing high dose external beam radiotherapy. Participants will undergo a single MR imaging session lasting 30 to 40 minutes, with the potential for an optional sub-study involving five additional sessions to assess inter-fraction motion. The goal is to develop high-quality MR images that can enhance the visualization of tumors during treatment, ultimately improving patient outcomes in radiotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults ≥ 18 years of age
* Patients deemed fit to undergo high dose external beam radiation therapy by their attending radiation oncologist

Exclusion Criteria:

* Patients with contraindications for MRI
* Patients who are unable to lie flat and still for the duration of the expected scan acquisition
* Patients who are unable to provide informed consent

Where it's running

• Cross Cancer Institute
  Edmonton, Alberta, Canada Recruiting

Study contacts

• Principal investigator: Nawaid Usmani, MD — Cross Cancer Institute, Alberta Health Services
• Study coordinator: Nawaid Usmani, MD
• Email: Nawaid.Usmani@ahs.ca
• Phone: 780-432-8518

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized two-fraction radiation for prostate cancer

  This study tests a two-fraction, MRI-guided radiation approach for intermediate- to high-risk prostate cancer to see if targeting nodules can be safely effective.

  Recruiting Phase 2 AHS Cancer Control Alberta · Lethbridge, Alberta · NCT07578519

• Morning vs Flexible Timing Pembrolizumab in Metastatic Non-Small Cell Lung Cancer

  This study tests whether giving pembrolizumab in the morning is better or the same as standard timing for people with metastatic non-small cell lung cancer who are eligible for this treatment.

  Recruiting Phase 2 AHS Cancer Control Alberta · Edmonton, Alberta · NCT06882174

• Inhaled budesonide to prevent recurrent checkpoint inhibitor–related pneumonitis

  This study tests whether adding inhaled budesonide to usual care can prevent recurrence of pneumonitis in adults who developed grade 2 or higher lung inflammation from checkpoint inhibitor immunotherapy.

  Recruiting Phase 2 AHS Cancer Control Alberta · Calgary, Alberta · NCT06860542

• Vedolizumab to prevent ICI-related diarrhea or colitis in cancer patients

  This study tests whether vedolizumab can prevent immune checkpoint inhibitor–related diarrhea or colitis in adults with unresectable or metastatic melanoma, lung, or kidney cancer starting immunotherapy.

  Recruiting Phase 2/3 AHS Cancer Control Alberta · Calgary, Alberta and 1 other locations · NCT06337695

• Using SBRT to treat liver metastases from colorectal cancer after initial treatment

  This study is testing if a special type of radiation therapy can help people with liver tumors from colorectal cancer feel better after their initial treatment.

  Recruiting Phase 2 AHS Cancer Control Alberta · Edmonton, Alberta · NCT05775146

• Mesalamine to prevent colitis from ipilimumab plus nivolumab

  This trial will try giving mesalamine to adults with advanced melanoma who are starting ipilimumab plus nivolumab to see if it lowers the chance and severity of immune-related diarrhea and colitis.

  Recruiting Phase 2 AHS Cancer Control Alberta · Edmonton, Alberta · NCT05663775

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.